News

The study reported that significantly more patients achieved at least a 75% improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo

The launch of bioequivalent generic version of SEROQUEL tablets is followed by the FDA approval of Dr Reddy’s ANDA. Quetiapine fumarate tablets in 25mg and 50mg are available

As per the agreement, NGM will apply its integrated discovery technology and in vivo screening platform to identify and validate physiologically-relevant metabolic targets that modulate beta-cell growth and

The milestone payment is related to the clinical trial application (CTA/IND) and projected initiation of a Phase 1 clinical trial. The HuCAL-derived, fully human antibody will be developed

MedeFile has agreed to form a 50/50 JV with a group of senior business and marketing executives in Spain. The JV partners and MedeFile International have agreed to

The suit is related to an abbreviated new drug application that Par filed with the FDA to market a generic version of DUEXIS tablets. The lawsuit claims infringement

The software, along with a patient portal, has been designed to better administer the clinical management of patient care and streamline internal reporting processes. Connexus provided Burman’s with

The Phase III randomized trial of farletuzumab is designed as a three-armed, double-blinded, controlled study. The study will evaluate farletuzumab at two different dosages in combination with second-line

OMONTYS is the once-monthly erythropoiesis-stimulating agent (ESA) for anemia. The approval was based on a new drug application, which included results from two Phase III studies. The studies